173 related articles for article (PubMed ID: 25025233)
1. Efficacy of imiquimod-based transcutaneous immunization using a nano-dispersed emulsion gel formulation.
Stein P; Gogoll K; Tenzer S; Schild H; Stevanovic S; Langguth P; Radsak MP
PLoS One; 2014; 9(7):e102664. PubMed ID: 25025233
[TBL] [Abstract][Full Text] [Related]
2. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
Lopez PA; Denny M; Hartmann AK; Alflen A; Probst HC; von Stebut E; Tenzer S; Schild H; Stassen M; Langguth P; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):252-259. PubMed ID: 28655469
[TBL] [Abstract][Full Text] [Related]
3. 9-Phenanthrol enhances the generation of an CD8
Hartmann AK; Aranda Lopez P; Zajac M; Freichel M; Schild H; Radsak MP; Stassen M
J Dermatol Sci; 2017 Sep; 87(3):260-267. PubMed ID: 28823644
[TBL] [Abstract][Full Text] [Related]
4. Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization.
Gogoll K; Stein P; Lee KD; Arnold P; Peters T; Schild H; Radsak M; Langguth P
Cell Immunol; 2016 Oct; 308():35-43. PubMed ID: 27318760
[TBL] [Abstract][Full Text] [Related]
5. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection.
Warger T; Rechtsteiner G; Schmid B; Osterloh P; Schild H; Radsak MP
Clin Rev Allergy Immunol; 2007 Feb; 32(1):57-66. PubMed ID: 17426361
[TBL] [Abstract][Full Text] [Related]
6. Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice.
Bialojan A; Sohl J; Rausch J; Aranda Lopez P; Denny M; Langguth P; Hartmann AK; Yagita H; Probst HC; Schild H; Radsak MP
Eur J Immunol; 2019 Nov; 49(11):2083-2094. PubMed ID: 31393597
[TBL] [Abstract][Full Text] [Related]
7. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization.
Stein P; Weber M; Prüfer S; Schmid B; Schmitt E; Probst HC; Waisman A; Langguth P; Schild H; Radsak MP
PLoS One; 2011; 6(11):e27911. PubMed ID: 22114725
[TBL] [Abstract][Full Text] [Related]
9. Comparative transcutaneous immunization with imiquimod-containing ointments and potential of in vitro methods to predict effects.
Gogoll K; Stein P; Wei H; Schild H; Radsak M; Langguth P
Biopharm Drug Dispos; 2012 May; 33(4):218-28. PubMed ID: 22473646
[TBL] [Abstract][Full Text] [Related]
10. Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection.
Hartmann AK; Bartneck J; Pielenhofer J; Meiser SL; Arnold-Schild D; Klein M; Stassen M; Schild H; Muth S; Probst HC; Langguth P; Grabbe S; Radsak MP
Front Immunol; 2023; 14():1238861. PubMed ID: 37727790
[TBL] [Abstract][Full Text] [Related]
11. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod.
Rechtsteiner G; Warger T; Osterloh P; Schild H; Radsak MP
J Immunol; 2005 Mar; 174(5):2476-80. PubMed ID: 15728450
[TBL] [Abstract][Full Text] [Related]
12. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
13. Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors.
Dell K; Koesters R; Gissmann L
Int J Cancer; 2006 Jan; 118(2):364-72. PubMed ID: 16052529
[TBL] [Abstract][Full Text] [Related]
14. UV exposure boosts transcutaneous immunization and improves tumor immunity: cytotoxic T-cell priming through the skin.
Stein P; Rechtsteiner G; Warger T; Bopp T; Fuhr T; Prüfer S; Probst HC; Stassen M; Langguth P; Schild H; Radsak MP
J Invest Dermatol; 2011 Jan; 131(1):211-9. PubMed ID: 20739947
[TBL] [Abstract][Full Text] [Related]
15. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine.
Johnston D; Bystryn JC
Vaccine; 2006 Mar; 24(11):1958-65. PubMed ID: 16310898
[TBL] [Abstract][Full Text] [Related]
16. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
17. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery.
Thomsen LL; Topley P; Daly MG; Brett SJ; Tite JP
Vaccine; 2004 Apr; 22(13-14):1799-809. PubMed ID: 15068864
[TBL] [Abstract][Full Text] [Related]
18. Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine.
Salem ML; Kadima AN; Zhou Y; Nguyen CL; Rubinstein MP; Demcheva M; Vournakis JN; Cole DJ; Gillanders WE
J Immunol; 2004 May; 172(9):5159-67. PubMed ID: 15100252
[TBL] [Abstract][Full Text] [Related]
19. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.
Shackleton M; Davis ID; Hopkins W; Jackson H; Dimopoulos N; Tai T; Chen Q; Parente P; Jefford M; Masterman KA; Caron D; Chen W; Maraskovsky E; Cebon J
Cancer Immun; 2004 Sep; 4():9. PubMed ID: 15384929
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]